Endogenex, Inc.
PLYMOUTH, MN · Founded 2017 · CIK 0001730881 · Biotech · Private
Therapeutic treatment solutions for Type 2 Diabetes management
endogenex.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $122M
- 6 Form D · Jun 2024
- 28 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 26
- 1 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20172018201920202021202220232024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $140,000 | |
| Private capital raised | Form D · SEC | $12,756,355 | |
| Private capital raised | Form D · SEC | $12,000,000 | |
| Private capital raised | Form D · SEC | $9,209,000 | |
| Private capital raised | Form D · SEC | $18,325,000 | |
| Private capital raised | Form D · SEC | $69,561,279 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1464 | Lapix Therapeutics Inc. | — | $12M |
| 1465 | ANDSON BIOTECH INC. | — | $8.3M |
| 1466 | GC Therapeutics | — | — |
| 1467 | Endogenex, Inc. | — | $122M |
| 1468 | Nob Hill Therapeutics, Inc. | — | $2.2M |
| 1469 | Aptevo Therapeutics Inc. | — | $5.6M |
| 1470 | Up Therapeutics LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Juliet BakkerDirector
- JULIET BAKKERDirector
- Michael BrenzelExecutive Officer
- Gerald BrunkDirector
- John DeedrickDirector · Executive Officer
- JOHN DEEDRICKDirector
- James EadieDirector
- JAMES EADIEDirector
- James Eadie, M.D.Director
- Paul HindrichsDirector · Executive Officer
- PAUL HINDRICHSDirector · Executive Officer
- ROBERT KUKUJLANExecutive Officer
- Robert KukuljanExecutive Officer
- Stacey PughDirector · Executive Officer
- Jeffrey TerrellDirector
Patents
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumgranted
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of The Duodenumapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
- Devices, Systems, And Methods For Pulsed Electric Field Treatment Of Tissueapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.